Nabumetone is indicated for acute and chronic relief of the signs and symptoms of Rheumatoid arthritis and Osteoarthritis.
Dosage & Administration
The starting and usual adult dose is 1000 mg daily taken as a single dose with or without food. The dosage may be
increased to 1500 mg or 2000 mg per day given either as a single dose or in two divided doses. Renal Impaired Patients:
No adjustment of the dosage of Nabumetone is generally necessary in patients with mild renal insufficiency. The maximum
starting doses of Nabumetone in patients with moderate or severe renal insufficiency should not exceed 750 mg or 500 mg,
respectively once daily. Following careful monitoring of renal function in patients with moderate or severe renal insufficiency,
daily doses may be increased to a maximum of 1,500 mg and 1,000 mg, respectively.
Fluid retention and edema have been observed in patients treated with Nabumetone. It should be used with caution in
patients with heart failure, hypertension or other conditions predisposing to fluid retention, serious gastrointestinal toxicity
such as ulceration, bleeding, and perforation with NSAID therapy. Nabumetone should be used with caution in patients with
severe hepatic impairment. Nabumetone is not recommended for use in children because the safety and efficacy in children
have not been established.
Use in Pregnancy and Lactation
There is no clinical trial experience with the use of Nabumetone during human pregnancy.
Use of Nabumetone during the first two trimesters of pregnancy should be restricted to situations where the potential benefit
to the mother justifies the potential risk to the fetus or nursing infant.
There is no clinical trial experience with the use of Nabumetone during human lactation. As the safety and efficacy of
Nabumetone in human lactation have not been established, its use is therefore not recommended.